A. Dixmier

Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial

Jean-Louis Pujol, A. Lavolé, Élisabeth Quoix et al. · Annals of Oncology · 2015 · 97 citations · Full text

Medicine, Oncology, Pharmacology +10

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

S. Couraud, Pierre-Jean Souquet, Christophe Paris et al. · European Respiratory Journal · 2015 · 85 citations

Medicine, Molecular Medicine, Oncology +16

Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study

Alexis B. Cortot, Clarisse Audigier-Valette, Olivier Molinier et al. · European Journal of Cancer · 2020 · 72 citations

Medicine, Oncology, Pharmacology +12

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial

Guy Meyer, Benjamin Besse, H. Doubre et al. · European Respiratory Journal · 2018 · 55 citations · Full text

Medicine, Oncology, Pharmacology +14

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

Fabrice Barlési, A. Dixmier, D. Debieuvre et al. · OncoImmunology · 2020 · 38 citations · Full text

Medicine, Oncology, Pharmacotherapy +16